TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A University of Missouri pilot study found that four weeks of low-dose rapamycin was associated with improved brain blood flow in healthy middle-aged adults carrying the APOE4 Alzheimer’s risk variant. The study did not test whether the drug prevents Alzheimer’s disease or preserves memory, and further research is needed.
Rapamycin, a drug used to prevent organ-transplant rejection, was associated with improved brain blood flow in healthy middle-aged adults carrying the APOE4 genetic variant, according to a University of Missouri pilot study. The finding points to a possible way to study early brain changes linked to Alzheimer’s risk, but it does not show that the drug prevents the disease or delays memory loss.
The study included healthy adults ages 45 to 65, both with and without APOE4, a gene variant associated with increased risk of Alzheimer’s disease. Participants received a low daily dose of rapamycin for four weeks. Researchers reported improved brain blood flow among APOE4 carriers; they did not observe the same benefit in participants without the variant.
The research team also reported that women carrying APOE4 had the largest improvements in blood flow. That result is an observation from this study, not proof that women would gain greater protection against Alzheimer’s from rapamycin. The report does not provide enough information to establish how broadly the findings apply beyond the participants studied.
The study, titled “Rapamycin increases cerebral blood flow and modulates metabolic, inflammatory, and microbiome profiles in healthy middle-aged APOE4 carriers: a pilot single-arm trial,” was published in the Journal of Cerebral Blood Flow & Metabolism. Its reported findings include changes in blood flow and other biological profiles. The researchers did not establish whether those changes persist after treatment or translate into better memory or a lower rate of Alzheimer’s disease.
A Possible Early Target in APOE4 Carriers
Alzheimer’s-related changes may begin before people notice memory problems. The researchers’ rationale is that reduced blood flow in parts of the brain can occur in APOE4 carriers years before symptoms, making circulation one potential early feature to investigate. A treatment that changes blood flow could offer researchers a measurable signal for studying early intervention, though that signal is not the same as evidence of disease prevention.
The results also raise a precision-medicine question: whether a drug might have different effects depending on a person’s genetic risk. In this pilot, the reported blood-flow improvement appeared in the APOE4 group rather than the non-carrier group. Larger and longer studies would be needed to determine whether that difference is reliable and clinically meaningful.
Rapamycin is already used for specific medical purposes, but this research does not support taking it to prevent Alzheimer’s. Its use, risks and benefits for this purpose have not been established by the reported study. The finding matters as a research lead, not as a prevention recommendation.
Products Worth Considering
Fitbit Sense 2 Health and Fitness Smartwatch, Shadow Grey/Graphite
Therabody Theragun Prime 6th Generation Deep Tissue Massage Gun, Black
OMRON Complete 2-in-1 Upper Arm Blood Pressure Monitor with EKG
As an affiliate, we earn on qualifying purchases.
From Mouse Findings to a Human Pilot
Study leader Ai-Ling Lin, a University of Missouri School of Medicine professor and researcher at the Roy Blunt NextGen Precision Health building, studies brain changes that may happen before Alzheimer’s symptoms. The report says her earlier mouse research found that rapamycin could slow aspects of brain aging and increase blood flow in animals carrying APOE4. The human pilot asked whether a similar blood-flow effect could be observed in adults at genetic risk who had not developed Alzheimer’s.
Rapamycin is an existing medication used to help prevent the immune system from rejecting transplanted organs and to treat certain rare conditions. Researchers have also studied its potential effects on biological aging. Those uses and areas of investigation do not establish that the drug is safe or effective for Alzheimer’s prevention. The new study’s short duration and focus on blood flow make it an early step rather than a test of long-term clinical outcomes.
“If we can slow down aging in the brain for those people most at risk, maybe we can reduce the risk of them developing Alzheimer’s disease.”
— Ai-Ling Lin, study leader and University of Missouri professor
Blood Flow Is Not Disease Prevention
The main unanswered question is whether improved blood flow leads to lasting benefits for brain health. The study did not show that participants had better memory, that any change continued after the four-week treatment, or that they were less likely to develop Alzheimer’s. A biological measure can be useful for research without proving a meaningful change in symptoms or disease risk.
The report describes a pilot trial involving a short course of treatment, but it does not establish the ideal dose, long-term safety for this purpose, or whether results would hold in a larger and more diverse group. The size and design also limit how confidently the findings can be generalized. The reported stronger effect among women with APOE4 will need further testing.
It is also unclear whether rapamycin’s effects on blood flow were directly responsible for changes in other measured biological profiles, or how those findings relate to future disease. No Alzheimer’s prevention benefit has been confirmed.
Testing Durability and Clinical Benefit
Further studies would need to test the findings in larger groups and follow participants for longer, including after the treatment ends. Researchers would also need to determine whether changes in brain blood flow are sustained and whether they relate to memory, other measures of brain function, or later Alzheimer’s outcomes.
Future research could examine whether responses differ by APOE4 status and sex, as the pilot results suggest may be worth investigating. It would also need to assess safety and dosing for any proposed use in people who do not otherwise take rapamycin. Until clinical trials establish those points, the reported result remains an early research finding, not a basis for using the drug to prevent Alzheimer’s disease.
Key Questions
What did the rapamycin study find?
Researchers reported improved brain blood flow after four weeks of low-dose rapamycin in healthy adults ages 45 to 65 who carried APOE4. They did not report the same benefit among participants without the variant.
Does rapamycin prevent Alzheimer’s disease?
The pilot study did not test or establish that rapamycin prevents Alzheimer’s, delays symptoms or preserves memory. It reported a change in blood flow, which requires further study to determine its clinical meaning.
Why did researchers study APOE4?
APOE4 is a genetic variant associated with increased Alzheimer’s risk. Researchers are investigating brain changes that may occur in carriers before noticeable memory problems begin.
Did women respond differently?
The researchers reported the largest blood-flow improvements among women carrying APOE4. This result needs confirmation in further research and does not show that women received greater protection from Alzheimer’s.
Should people take rapamycin to lower Alzheimer’s risk?
The study does not establish rapamycin as a prevention treatment. It was a short pilot study of blood flow, not a clinical test of Alzheimer’s prevention or long-term safety for that purpose.
Source: sciencedaily.com
